Supplemental Table S2

			sensitivity (rank)		
cell line	variant	predicted impact	olaparib	talazoparib	niraparib
A673	*TP53*	pathogenic	34	31	32
	ERCC2	benign/likely benign			
CADOES1	*SLX4*	pathogenic	42	13	
	APC	likely benign			
SKPNDW	*FANCM*	pathogenic			48
	TP53	likely pathogenic			
RDES	*TP53*	pathogenic			
MHES1	*TP53*	likely pathogenic	41		22
ES1	*TP53*	pathogenic	23	23	
ES3	*TP53*	likely pathogenic			
ES5	*PTCH2*	likely benign			
	TP53	pathogenic			
ES6	*TP53*	likely pathogenic			
ES7	*POLE*	likely benign	21	18	6
	FK8P3	VUS			
	FANCM	pathogenic			
	ERCC4	benign/likely benign			
	TP53	likely pathogenic			
ES8	*TP53*	pathogenic	10	5	8
EW16	*TP53*	likely pathogenic			
EW22	*TP53*	pathogenic	14	8	10
EW24	*APC*	benign			
	TP53	likely pathogenic			

benign/likely benign
variant of unknown significance
pathogenic/likely pathogenic

Supplemental Table S2.
Prevalence of somatic DNA damage repair gene variants in Ewing cell lines included in original studies of PARP inhibition. Cancer cell line encyclopedia (CCLE) data was queried for somatic mutations in DNA damage repair gene mutations in the 14 Ewing sarcoma cell lines listed. The predicted/known impacts of the somatic mutations and sensitivity rank (sensitivity to a compound as compared to all other cells lines in the CCLE) to the PARP inhibitors olaparib, talazoparib and niraparib are also noted.